|Last Price||Today's Change||52-Week Range||Trading Volume|
|4.84||-0.82 (-14.49%)||4.83 - 10.86||5.0 million (Above Avg)|
Market data as of 4:00PM 08/22/14. Quotes are delayed by at least 15 min.
These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
|Performed well consistently?||Fail|
|Avoids excess debt?||Fail|
|Converting sales to profits?||Fail|
|Shareholder's money handled rationally?||Neutral|
|Increased shareholder value?||Neutral|
|Consistently increased owner earnings?||Fail|
|Sells at 25% discount to intrinsic value?||Fail|
These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
|Pays a cash dividend?||Neutral|
|Room to increase dividends?||Fail|
|Increased earnings over time?||Neutral|
|Borrows within reasonable limits?||Pass|
|Stock is undervalued?||Fail|
|Have investors caught on?||Fail|
|Has support of institutional investors?||Fail|
|Has sufficient liquidity?||Pass|
Ampio reports that due to temperature deviations below product specifications during shipments to the Ampion™ STEP Study clinical sites, release of data will be delayed
PR Newswire - Thursday 08/21/2014 7:56 AM ET
Analysis Of Available Data From Optimeyes Study (Blinded And Open Label) Of Optina™ For The Treatment Of Diabetic Macular Edema (DME) Indicates Potential For Significant Clinical Benefit
PR Newswire - Wednesday 08/20/2014 7:56 AM ET
Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
PR Newswire - Tuesday 08/19/2014 7:56 AM ET
Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial
PR Newswire - Monday 08/18/2014 8:00 AM ET
Luoxis Broadens Global Research Network for RedoxSYS™ oxidation-reduction potential (ORP) diagnostic system; Announces 17 Studies Currently Underway and Additional 30 Studies Set to Begin in 2014
PR Newswire - Monday 08/11/2014 8:00 AM ET
Ampio announces positive results on the open label portion of the Multiple injection Study of Ampion™ in patients with osteoarthritis of the knee.
PR Newswire - Tuesday 08/05/2014 8:00 AM ET
Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion™ in the new facility.
PR Newswire - Wednesday 07/30/2014 8:00 AM ET
Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado
PR Newswire - Wednesday 07/23/2014 8:00 AM ET
|Revenue Growth (1yr)||17.86%|
|Net Income Growth (1yr)||--|